MHLW Releases New Drug Pricing Report Amid Deadlock In Price Revision Exemption Debate
This article was originally published in PharmAsia News
Executive Summary
Japan's Ministry of Health, Labor and Welfare submitted a status report on new drug pricing in 2008 to the Central Social Medical Insurance Agency, also called Chuikyo. The report showed that drug prices calculated by using similar drug methods were 10 percent lower than overseas average prices
You may also be interested in...
Could Japan's Chuikyo Embrace NICE Model As New Chairman Takes Reign?
The new chairman of Japan's Central Social Medical Insurance Council (Chuikyo), the committee that determines drug pricing for Japan's National Health Insurance, will consider the possibility of linking drug pricing to health technology assessments, similar to the UK's National Institute for Health and Clinical Excellence
Could Japan's Chuikyo Embrace NICE Model As New Chairman Takes Reign?
The new chairman of Japan's Central Social Medical Insurance Council (Chuikyo), the committee that determines drug pricing for Japan's National Health Insurance, will consider the possibility of linking drug pricing to health technology assessments, similar to the UK's National Institute for Health and Clinical Excellence
Japan To Lower Price Of Eight Drugs From Takeda, Novartis, BMS And Chugai By 12-18 Percent
As part of an ongoing re-pricing policy for drugs that have seen expanded market share, Japan's Ministry of Health, Labor and Welfare has decided to lower the price on eight drugs effective April 1